Biocon Biologics CEO Shreehas Tambe Projects FY27 Growth from New Approvals and GLP-1 Drug Pipeline

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Biocon Biologics Targets FY27 Growth with New Approvals, GLP-1 Pipeline

With the third quarter earnings season drawing to a close, there will be a beeline of companies reporting their quarterly results in the upcoming week. A combination of Nifty 50 companies, F&O stocks, and new listings as well, will be part of the list for the week. Here's a look at some of the major earnings that you should have your eyes on:

C

CNBC TV18•13-02-2026, 16:26

Biocon Biologics Targets FY27 Growth with New Approvals, GLP-1 Pipeline

•Biocon Biologics anticipates significant growth in FY2027 driven by new product approvals and expansion into high-margin markets.
•The company is focusing on its GLP-1 drug pipeline, including Liraglutide and Semaglutide, for diabetes and weight loss treatments.
•Liraglutide has seen success in Europe and emerging markets, with US approval expected soon; Semaglutide is being developed for multiple geographies.
•Biocon Biologics aims to strengthen its balance sheet, reducing its debt-to-EBITDA ratio from over 4x to 2.5x, with a target of closer to 1x.
•The company reported Q3FY26 revenues of ₹4,173 crore, a net profit of ₹143.8 crore, and an EBITDA margin of 28%.

Read Full Article on Cnbc in English

✦

More like this

✦

More like this

Biocon./Reuters

Biocon acquires Biocon Biosphere, Pharma for ₹315 Cr; Q3 net profit rises to ₹143.8 Cr

Representational image (Image: News18)

Biocon Q3 Net Profit Soars 5-Fold to Rs 144 Cr, Driven by Generics & Biosimilars

Fitch Upgrades Biocon Biologics Outlook to Positive, Affirms BB- Rating

Fitch Upgrades Biocon Biologics Outlook to Positive, Affirms BB- Rating

zydus life share price, zydus life stock, zydus life shares, zydus life, zydus life Q3, zydus life Q3 earnings, zydus life Q3 results, zydus life earnings, zydus life results, zydus life net profit, zydus life revenue, zydus life EBITDA, zydus life margin,

India Can Be Biologics Hub with Right Execution: Wockhardt Chairman

AstraZeneca Pharma Q3 Revenue Soars 39% on Oncology, Biopharma Growth; Margins Slip

AstraZeneca Pharma Q3 Revenue Soars 39% on Oncology, Biopharma Growth; Margins Slip

Representational image (Image: News18)

Abbott, Novo Nordisk Partner to Launch New Diabetes Medication in India